Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
NCT05168475 · Cambridge University Hospitals NHS Foundation Trust · PHASE2 · terminated · last registry update 2025-06-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “NIHR withdrawal of funding” | – | Registry record, Cambridge University Hospitals NHS Foundation Trust |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-03Results posted on the registry: Hawaii Pacific Health, Doxycycline + Placebo (NCT01917721)
- 2026-05-06Also stopped (terminated): Mats Remberger, Decidua Stroma Cells (DSC) + Best available Treatment (BAT) (NCT04118556)
- 2026-05-04Also stopped (suspended): Robert Flavell, MD, PhD, 89Zr-DFO-CZP (NCT03546335)
- 2026-03-11Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Infliximab precision dosing (NCT04974099)
- 2026-03-11Also stopped (terminated): Children's Hospital Medical Center, Cincinnati, Infliximab precision dosing (NCT04974099)
- 2025-12-26Also stopped (withdrawn): Therakos LLC, Methoxsalen + Infliximab (NCT06646016)
- 2025-12-02Results posted on the registry: The Leeds Teaching Hospitals NHS Trust, Methotrexate + Golimumab (NCT04108468)
- 2025-11-20Also stopped (terminated): Assistance Publique Hopitaux De Marseille, Methotrexate + Methotrexate Placebo (NCT02829424)
- 2025-11-14Results posted on the registry: Janssen Research & Development, LLC, Golimumab + Infliximab (NCT03596645)
- 2025-11-04Results posted on the registry: University of California, San Diego, Infliximab + Anakinra (NCT04898231)
- 2025-10-16Results posted on the registry: Janssen Research & Development, LLC, Placebo + Nipocalimab (NCT06028438)
- 2025-10-06Also stopped (withdrawn): Abu Dhabi Stem Cells Center, Anti-TNF + JAK inhibitor (NCT05379322)
- 2025-06-04Results posted on the registry: Institute for Clinical and Experimental Medicine, MabCampath, + Remicade (NCT02711202)
- 2025-05-28Results posted on the registry: Alvotech Swiss AG, AVT05 + Simponi (NCT05632211)
- 2025-04-29Also stopped (terminated): Janssen Research & Development, LLC, Placebo + Ustekinumab 45 mg (NCT02437162)
- 2025-04-29Also stopped (terminated): Janssen Research & Development, LLC, Placebo + Ustekinumab 45 mg (NCT02438787)
- 2025-02-21Results posted on the registry: Boston Medical Center, SHINGRIX (NCT03591770)
- 2025-02-21Also stopped (terminated): Boston Medical Center, SHINGRIX (NCT03591770)
- 2025-02-11Results posted on the registry: University Ghent, Golimumab (NCT03270501)
- 2025-02-06Also stopped (terminated): Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Infliximab (NCT03937609)
- 2025-02-04Also stopped (terminated): Janssen Scientific Affairs, LLC, Infliximab (NCT02566889)
- 2024-12-30Results posted on the registry: University of Miami, Advanced therapy only without dietary intervention (NCT04505410)
- 2024-10-28Phase 3 first posted: McMaster University, Upadacitinib Oral Product (NCT06660693)
- 2024-10-23Results posted on the registry: UCB BIOSCIENCES GmbH, Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) (NCT01550003)
- 2024-09-26Phase 3 first posted: JAROSLAW KIERKUS, Infliximab (NCT06614387)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision